![From Informative to Transformative: How Real-World Data is Fueling Healthcare Innovation](https://trinetx.com/wp-content/uploads/2024/07/2024-Alantra-Podcast_Featured-Image.png)
![From Informative to Transformative: How Real-World Data is Fueling Healthcare Innovation](https://trinetx.com/wp-content/uploads/2024/07/2024-Alantra-Podcast_Featured-Image.png)
![Equity in Action: Data-Driven Strategies to Advance Diversity in Clinical Trials](https://trinetx.com/wp-content/uploads/2024/07/Social-Graphics-Blog-Equity-in-Action_Featured-Image.png)
Equity in Action: Data-Driven Strategies to Advance Diversity in Clinical Trials
“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical trials can have significant and wide-ranging consequences — impacting the quality and applicability of...![Harnessing Real-World Data to Revolutionize Chronic Lymphocytic Leukemia Research](https://trinetx.com/wp-content/uploads/2024/07/2024-EHA-Blog_Featured-Image-1.png)
Harnessing Real-World Data to Revolutionize Chronic Lymphocytic Leukemia Research
Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western world and is the most common type of leukemia in adults, with over 100,000 new global incidence cases and over...![Real-World Data and Real-World Evidence: Shaping Global Regulatory Practices](https://trinetx.com/wp-content/uploads/2024/07/2024-DIA-Infographic_Featured-Image-300x188-1.png)
Real-World Data and Real-World Evidence: Shaping Global Regulatory Practices
This infographic blog post is derived from the recent article by Jeffrey Brown, PhD, The Role of RWD and RWE in Shaping Global Regulatory Practices, published in the June 2024 issue of DIA Global Forum. Download the Infographic Summary Courtesy of TriNetX Experts...![Network Spotlight: University Medical Center Schleswig-Holstein (UKSH)](https://trinetx.com/wp-content/uploads/2024/07/2024-05-Network-Spotlight_UKSH_Featured-Image.png)
Network Spotlight: University Medical Center Schleswig-Holstein (UKSH)
We are honored to recognize UKSH for their partnership with TriNetX. In the ever-evolving landscape of healthcare, collaboration isn’t just beneficial; it’s essential. TriNetX is proud to partner with our network to advance healthcare through rigorous research,...![Real-World Data To Improve Clinical Trial Design](https://trinetx.com/wp-content/uploads/2024/07/2024-Industry-Dive-TriNetX_WP-Featured-Image.png)
Real-World Data To Improve Clinical Trial Design
By Arnaub Chatterjee, Chief Solutions and Product Officer at TriNetX Many clinical trials struggle to enroll patients, hindering meaningful results and delaying the delivery of therapies to patients. Real-world data (RWD) addresses this by overcoming barriers such as...![The Growing Influence of Real-World Data and Evidence](https://trinetx.com/wp-content/uploads/2024/04/2024-04-Growing-Influence-of-RWD-Blog_Featured-Image.png)
The Growing Influence of Real-World Data and Evidence
Some of the most prominent and visible roles of real-world data (RWD) and real-world evidence (RWE) are regulatory and clinical decision-making and disease research. However, RWD and RWE have been growing in influence in many other areas of healthcare and in regions...![Detecting Pancreatic Cancer with TriNetX AI: The PDAC Risk Model Breakthrough](https://trinetx.com/wp-content/uploads/2024/03/Blog-PDAC_LinkedIn_detect-1080x628.png)
Detecting Pancreatic Cancer with TriNetX AI: The PDAC Risk Model Breakthrough
Powered By TriNetX MIT and BIDMC’s study published by The Lancet introduces PRISM, a model for early pancreatic cancer risk, using a database of over 156 million de-identified US patients from TriNetX, LLC. PRISM accurately forecasts pancreatic cancer risk 18...![Growing Need for Diversity in Clinical Trials](https://trinetx.com/wp-content/uploads/2024/01/Blog-TDO-DEI_LinkedIn_headline-1080x628.png)
Growing Need for Diversity in Clinical Trials
By Akiko Shimamura, SVP, Trial Design and Optimization, TriNetX Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.[1] In 2021, the...![TriNetX Joins CERTAINTY Project to Enhance Cancer Immunotherapy](https://trinetx.com/wp-content/uploads/2024/01/2024-01-30-CERTAINTY_LinkedIn-1080x627.png)